AVTX

Rating neutralTentativeAI Memo

Avalo Therapeutics

As of 2026-10-23/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-23 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Abdakibart registrational Phase 3 initiation • 2027-06-30

Base target: $7 / p=45% prob

Biggest risk

Avalo remains dependent on translating Phase 2 findings into a successful pivotal program. AbbVie's newly reported positive Phase 3 HS results add a credible competitive threat, although they cannot be compared directly with LOTUS. AbbVie release

Invalidation

Break below $4 or thesis failure.

What would change my mind?

Positive LOTUS topline results support advancement of abdakibart, while Avalo reported $472.2 million in cash, cash equivalents, and investments at June 30, 2026 and expected runway into 2029. Successful Phase 3 initiation could make the program more investable. [#SEC-8K-2026-08-06]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-23

Base target

p=45%

Bull target

$12

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

HS competitor data may reset the efficacy bar
AVTX-010 IND submission
Positive LOTUS topline results support advancement of abdakibart, while Avalo reported $472.2 million in cash, cash equivalents, and investments at June 30, 2026 and expected runway into 2029.

BearKey bullets

AbbVie's positive Phase 3 lutikizumab HS results increase competitive pressure; cross-trial efficacy rankings would be misleading.
AbbVie release
Avalo reported $23.4 million of second-quarter R&D expense, including a $10 million abdakibart development milestone; Phase 3 and AVTX-010 could raise future spending despite stated runway into 2029.

WatchKey bullets

Abdakibart registrational Phase 3 initiation

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $7 (p=45%)

Target spread vs base: +71% / -50%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $7 (p=45%)Bear Target: $4 (p=30%)

Commentary

The prior thesis centered on an anticipated LOTUS readout; by August, Avalo had reported positive topline results and shifted focus to Phase 3 execution and AVTX-010. [#SEC-8K-2026-08-06] The October 22 AbbVie result warrants monitoring, but the packet does not establish AVTX's post-announcement price reaction, analyst revisions, or current social, options, short-interest, or employee metrics; zeroes above indicate unavailable measurements, not neutral readings. The deterministic directional prior is negative, and low coverage limits conviction.

As of 2026-10-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

HS competitor data may reset the efficacy bar
AVTX-010 IND submission

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$7 / p=45% prob

Bear Target (Scenario probability)

$4 / p=30% prob

Analysis 2026-10-23 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-06-30
Abdakibart registrational Phase 3 initiation
After reporting positive Phase 2 LOTUS topline results, Avalo said it plans to initiate a registrational Phase 3 HS program in the first half of 2027. Trial design, timing, and execution remain the principal value-setting questions. [#SEC-8K-2026-08-06]
Prob 75.00% • Move 25.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

HS competitor data may reset the efficacy bar
2026-10-23
AbbVie reported on October 22 that its Phase 3 lutikizumab trial met its Week 16 HiSCR75 primary endpoint in hidradenitis suppurativa (HS). This is a competitive read-through, not evidence that Avalo's trial will fail; cross-trial efficacy comparisons are unreliable. AbbVie release
Prob 70% • Move -12% • Priced-in 20%

Long-term Catalysts

Months to a year

AVTX-010 IND submission
2027-06-30
Avalo expects to submit an IND for its long-acting anti-IL-1β antibody AVTX-010 in the first half of 2027. This could broaden the pipeline, but it remains preclinical and adds development spending before clinical validation. [#SEC-8K-2026-08-06]
Prob 65% • Move 12% • Priced-in 30%

Risks

AbbVie's positive Phase 3 lutikizumab HS results increase competitive pressure; cross-trial efficacy rankings would be misleading. AbbVie release
Avalo reported $23.4 million of second-quarter R&D expense, including a $10 million abdakibart development milestone; Phase 3 and AVTX-010 could raise future spending despite stated runway into 2029. [#SEC-8K-2026-08-06]
Pivotal-trial design, enrollment, safety, and efficacy may differ from Phase 2 LOTUS; Avalo's stated first-half 2027 start is a plan, not a completed milestone. [#SEC-8K-2026-08-06]

Peers

Symbol	Summary
MLTX	Direct HS clinical-development comparator: MoonLake is studying sonelokimab in Phase 3. Its different mechanism, later stage, and broader program make it unsuitable as a simple valuation multiple. MoonLake release
ZURA	HS clinical-development comparator through its tibulizumab Phase 2 study, but mechanism and pipeline breadth differ from Avalo. Zura SEC-filed update

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-23

Loading AI feed…

Symbol

Summary

MLTX

Direct HS clinical-development comparator: MoonLake is studying sonelokimab in Phase 3. Its different mechanism, later stage, and broader program make it unsuitable as a simple valuation multiple. MoonLake release

ZURA

HS clinical-development comparator through its tibulizumab Phase 2 study, but mechanism and pipeline breadth differ from Avalo. Zura SEC-filed update